We’re glad to see you’re enjoying ReachMD…but how about a more personalized experience?
The Role of Chemotherapy and Immunotherapy in ROS1-Rearranged NSCLC
Charu Aggarwal, MD, MPH
Alexander Drilon, MD
Next-Generation TKI Therapy for ROS1-Rearranged NSCLC
First-Line Targeted Therapies for ROS1 Fusion-Positive Lung Cancers
Bispecific Antibodies: The Newest Immunotherapy on the Block for RRMM
Sagar Lonial, MD, FACP
Caitlin Costello, MD
Clinical Challenges With Triple-Class or Penta-Refractory MM
Later-Line Targeted Therapies for ROS1 Fusion-Positive Lung Cancers
Step-Up Dosing of Bispecific Antibodies: The Need for Hospitalization
Integrating Bispecific Antibodies Into Clinical Practice
Intracranial Activity of ROS1 TKIs
Safety and Tolerability of ROS1 Tyrosine Kinase Inhibitors
Considerations for Dosing Bispecific Antibodies
Case: Treatment Selection for ROS1-Rearranged NSCLC Patient with Brain Metastases
Treatment Strategy of ROS1-Rearranged NSCLC in TKI-Naive Patient
Current Guidelines and Real-World Evidence for ROS1 Testing in NSCLC
Approved Bispecific Antibodies for RRMM: Review of the Pivotal Trials
Press cancel to remain on ReachMD. Press the link below or the continue button to keep going.
Stay current with the best on medical education